908 Devices Business Summary

908 Devices Inc. (MASS) operates a high-margin hardware-as-a-platform model, generating revenue through the sale of purpose-built handheld mass spectrometry devices and a growing stream of recurring revenue from consumables, service contracts, and specialized training. Following the strategic divestiture of its bioprocessing portfolio to Repligen in March 2025, the company has consolidated its operations into a single primary segment focused on "vital health, safety, and defense-tech" applications. Its core product line, including the MX908, XplorIR, and the newly launched VipIR, provides point-of-need chemical analysis for law enforcement, military, and hazmat teams. 908 Devices competes directly with established analytical instrument giants such as Bruker, Agilent Technologies, and Thermo Fisher Scientific, positioning itself as the specialized leader in miniaturized, ruggedized mass spectrometry for field forensics and threat detection. The company was co-founded by CEO Kevin J. Knopp, PhD, and Christopher D. Brown, PhD, both of whom previously held leadership roles at Ahura Scientific before its acquisition by Thermo Fisher. The current executive team includes Joseph H. Griffith as Chief Financial Officer and Kevin McCallion, PhD, as Senior Vice President of Products & Production. Christopher Brown remains a key strategic influence, having transitioned from Chief Product Officer to the Board of Directors in June 2025. The board is chaired by Kevin Hrusovsky, the former CEO of Quanterix, and the company maintains a strong institutional investor base, including notable positions held by the Baron Health Care Fund. This leadership team brings deep pedigree in commercializing disruptive analytical technologies, specifically in transitioning complex laboratory capabilities to portable, user-friendly field formats.